APA (7th ed.) Citation

Roberts, C., Peters, J., Sazonvos, A., Goodman, N., Sharip, M., Smith, R., . . . Abdelmeguid, A. (2025). Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource. Alimentary Pharmacology & Therapeutics, 62(6), 630. https://doi.org/10.1111/apt.70232

Chicago Style (17th ed.) Citation

Roberts, Christopher, et al. "Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource." Alimentary Pharmacology & Therapeutics 62, no. 6 (2025): 630. https://doi.org/10.1111/apt.70232.

MLA (9th ed.) Citation

Roberts, Christopher, et al. "Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource." Alimentary Pharmacology & Therapeutics, vol. 62, no. 6, 2025, p. 630, https://doi.org/10.1111/apt.70232.